Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide for patients with recurrent lymphoma.

Barbara Pro1, Anas Younes, Maher Albitar

  • 1Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. bpro@mdanderson.org

Cancer
|March 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study.

Blood neoplasia·2026
Same author

Serum proteomic and single-cell transcriptomic profiling reveals immunoproteomic features distinguishing early-stage mycosis fungoides from atopic dermatitis.

The Journal of investigative dermatology·2026
Same author

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Leukemia & lymphoma·2026
Same author

Staging imaging reveals clinically significant comorbidities in primary cutaneous marginal zone lymphoma: A retrospective study.

Journal of the American Academy of Dermatology·2026
Same author

Cutaneous B-Cell lymphoma incidence trends in the United States: A surveillance, epidemiology, and end results analysis of 10,975 cases.

The Journal of investigative dermatology·2026
Same author

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Thalidomide showed limited effectiveness as a single treatment for patients with advanced lymphoma, including non-Hodgkin lymphoma and Hodgkin disease. Further research is needed to explore its potential in treating these lymphoid malignancies.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Thalidomide is effective in multiple myeloma.
  • Its efficacy in other lymphoid tumors is not well-established.

Purpose of the Study:

  • To evaluate thalidomide's activity in patients with recurrent or refractory non-Hodgkin lymphoma and Hodgkin disease.
  • To assess the impact of thalidomide on serum angiogenesis factors.

Main Methods:

  • Nineteen heavily pretreated patients received escalating doses of thalidomide (200-800 mg/day).
  • Treatment continued until disease progression or toxicity.
  • Serum angiogenesis factors were measured pre- and post-treatment.

Main Results:

  • One patient (5%) with gastric mucosa-associated lymphoid tissue lymphoma achieved a complete response.

Related Experiment Videos

  • Three patients (16%) achieved stable disease.
  • Limited overall activity observed in this heavily pretreated population.

    • Conclusions:

    • Thalidomide demonstrates minimal single-agent activity in patients with recurrent or refractory lymphoma.
    • The drug's utility in this setting appears limited, warranting further investigation into combination therapies or alternative agents.